US20150258011A1 - Treatment of keratinized tissues - Google Patents
Treatment of keratinized tissues Download PDFInfo
- Publication number
- US20150258011A1 US20150258011A1 US14/214,930 US201414214930A US2015258011A1 US 20150258011 A1 US20150258011 A1 US 20150258011A1 US 201414214930 A US201414214930 A US 201414214930A US 2015258011 A1 US2015258011 A1 US 2015258011A1
- Authority
- US
- United States
- Prior art keywords
- acid
- composition
- keratinized tissue
- keratinized
- activated gas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 114
- 239000000203 mixture Substances 0.000 claims abstract description 182
- 239000002253 acid Substances 0.000 claims abstract description 161
- 238000000034 method Methods 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 58
- -1 alkali metal bicarbonate Chemical class 0.000 claims description 37
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 26
- 239000002243 precursor Substances 0.000 claims description 25
- 239000011573 trace mineral Substances 0.000 claims description 24
- 235000013619 trace mineral Nutrition 0.000 claims description 24
- 239000007789 gas Substances 0.000 claims description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- 239000008121 dextrose Substances 0.000 claims description 17
- 210000003491 skin Anatomy 0.000 claims description 17
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 16
- 229910001508 alkali metal halide Inorganic materials 0.000 claims description 16
- 235000014104 aloe vera supplement Nutrition 0.000 claims description 16
- 229940101267 panthenol Drugs 0.000 claims description 16
- 235000020957 pantothenol Nutrition 0.000 claims description 16
- 239000011619 pantothenol Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 14
- 230000002378 acidificating effect Effects 0.000 claims description 14
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 208000003251 Pruritus Diseases 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 11
- 239000002563 ionic surfactant Substances 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 10
- 239000002736 nonionic surfactant Substances 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- 210000004927 skin cell Anatomy 0.000 claims description 9
- 201000004624 Dermatitis Diseases 0.000 claims description 8
- 230000001668 ameliorated effect Effects 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 7
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 5
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 5
- 235000011054 acetic acid Nutrition 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 150000003863 ammonium salts Chemical class 0.000 claims description 5
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 5
- 235000015165 citric acid Nutrition 0.000 claims description 5
- 235000019253 formic acid Nutrition 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 235000006408 oxalic acid Nutrition 0.000 claims description 5
- 235000011007 phosphoric acid Nutrition 0.000 claims description 5
- 229940116269 uric acid Drugs 0.000 claims description 5
- 208000002782 Acneiform Eruptions Diseases 0.000 claims description 4
- 208000022715 Autoinflammatory syndrome Diseases 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 4
- 206010033554 Palmoplantar keratoderma Diseases 0.000 claims description 4
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 4
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 4
- 208000002352 blister Diseases 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000005865 ionizing radiation Effects 0.000 claims description 4
- 206010037844 rash Diseases 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 description 81
- 210000004761 scalp Anatomy 0.000 description 33
- 208000001840 Dandruff Diseases 0.000 description 24
- 125000000217 alkyl group Chemical group 0.000 description 19
- 125000003118 aryl group Chemical group 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 8
- 239000004299 sodium benzoate Substances 0.000 description 8
- 235000010234 sodium benzoate Nutrition 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 229940075560 sodium lauryl sulfoacetate Drugs 0.000 description 7
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- 230000007803 itching Effects 0.000 description 6
- 239000007793 ph indicator Substances 0.000 description 6
- 208000008742 seborrheic dermatitis Diseases 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- 241000555676 Malassezia Species 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003746 feather Anatomy 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 206010000502 Acne cosmetica Diseases 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- 208000009766 Blau syndrome Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061217 Infestation Diseases 0.000 description 2
- 208000015217 Keratosis pilaris atrophicans Diseases 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 208000005995 Lichenoid Eruptions Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000002366 Nut Hypersensitivity Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010043866 Tinea capitis Diseases 0.000 description 2
- 241000159241 Toxicodendron Species 0.000 description 2
- 241000159243 Toxicodendron radicans Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003571 Vitamin B5 Natural products 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052790 beryllium Inorganic materials 0.000 description 2
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000024386 fungal infectious disease Diseases 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 201000010854 nut allergy Diseases 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 201000005354 penicillin allergy Diseases 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000006934 radiodermatitis Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229910052712 strontium Inorganic materials 0.000 description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 235000009492 vitamin B5 Nutrition 0.000 description 2
- 239000011675 vitamin B5 Substances 0.000 description 2
- JOQDDLBOAIKFQX-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6,6-dodecafluoro-1,6-diiodohexane Chemical compound FC(F)(I)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)I JOQDDLBOAIKFQX-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010013709 Drug ineffective Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000002192 heptalenyl group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/22—Gas releasing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/884—Sequential application
Definitions
- Keratinized tissues such as hair, skin, nails, fur, feathers, and the like may exhibit a variety of conditions which may have cosmetic or health implications. For example, hair may become dull, stiff, oily, easily tangled, easily frayed and the like as a result of environmental factors, endogenous health conditions, or other factors. Likewise, keratin on the surface of skin may become irritated, scaly, rough, and the like, again as a result of environmental factors, endogenous health conditions, or other factors. Areas of high skin/hair interface, such as at the scalp, may present additional issues, such as dandruff. Similar issues may affect skin, claws, fur, and feathers of nonhuman animals. Although many treatments exist to treat various conditions of keratinized tissues such treatments may suffer from issues of cost, lack of efficacy, lack of efficacy for multiple related conditions across both skin and hair, requirement for prescription, harsh, irritating, or dangerous chemicals, and the like.
- the present disclosure appreciates that ameliorating various conditions of keratinized tissues may be a challenging endeavor.
- a method for treating a keratinized tissue condition in a subject in need thereof.
- the method may include conducting one or more treatment cycles on the keratinized tissue.
- Each treatment cycle may include contacting the keratinized tissue with an acid-activated gas-generating composition.
- Each treatment cycle may include contacting the keratinized tissue with an acid composition.
- Each treatment cycle may include allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue.
- a kit may be configured for treating a keratinized tissue condition in a subject in need thereof.
- the kit may include an acid-activated gas-generating composition or a precursor thereof included in a first reservoir.
- the kit may include an acid composition or a precursor thereof included in a second reservoir separated from the first reservoir.
- the kit may include instructions.
- the instructions may include directions to conduct one or more treatment cycles on the hair and/or skin. Each treatment cycle may include contacting the keratinized tissue with the acid-activated gas-generating composition. Each treatment cycle may include contacting the keratinized tissue with the acid composition.
- Each treatment cycle may include allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue.
- FIG. 1 depicts a flow chart of a method 100 for treating a keratinized tissue condition in a subject in need thereof.
- a method 100 for treating a keratinized tissue condition in a subject in need thereof.
- FIG. 1 depicts a flow chart of a method 100 .
- Method 100 may include 102 conducting one or more treatment cycles on the keratinized tissue. Each treatment cycle may include 104 contacting the keratinized tissue with an acid-activated gas-generating composition. Each treatment cycle may include 106 contacting the keratinized tissue with an acid composition. Each treatment cycle may include 108 allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue.
- the keratinized tissue condition may be at least partly ameliorated.
- the keratinized tissue condition may include one or more of, for example: acneiform eruptions, e.g., acne cosmetica, acne vulgaris , and the like; autoinflammatory syndromes, e.g., Blau syndrome, chronic infantile neurologic cutaneous and articular syndrome, and the like; chronic blistering, e.g., phemphigus conditions, and the like; conditions of the skin appendages, e.g., folliculitis, keratosis pilaris atrophicans, and the like; dermatitis, e.g., atopic dermatitis, contact dermatitis, eczema, pustular dermatitis, seborrheic dermatitis, and the like; drug or agent eruptions, e.g., penicillin allergy, nut allergy, poison oak or poison ivy, and the like; infection-related, e.g.
- At least one treatment cycle may include contacting the keratinized tissue with the acid-activated gas-generating composition before contacting the keratinized tissue with the acid composition. Additionally or alternatively, at least one treatment cycle may include contacting the keratinized tissue with the acid composition before contacting the keratinized tissue with the acid-activated gas-generating composition. The method may also include conducting two or more of the treatment cycles in succession on the keratinized tissue. Additionally or alternatively, at least one treatment cycle may include rinsing the keratinized tissue after allowing the acid composition and the acid-activated gas-generating composition to react effective to generate the gas at the keratinized tissue. Additionally or alternatively, at least one treatment cycle comprising contacting the keratinized tissue with the acid composition after conducting the one or more treatment cycles on the keratinized tissue.
- the method may include adjusting the keratinized tissue to between a pH of about 4.5 and a pH of about 6.5 after conducting the one or more treatment cycles on the keratinized tissue.
- the method may include adjusting the keratinized tissue to between a pH of about 4.5 and a pH of about 5.5 after conducting the one or more treatment cycles on the keratinized tissue.
- the acid-activated gas-generating composition may include one or more gas generating agents, including one or more of: an alkali metal carbonate, alkali earth metal carbonate, an alkali metal bicarbonate, an alkali earth metal bicarbonate, or carbonic acid.
- alkali metals may include lithium, sodium, potassium, cesium, and the like.
- Alkali earth metals may include beryllium, magnesium, calcium, strontium, barium, and the like.
- the acid composition may include an acid including one or more of: lactic acid, acetic acid, formic acid, citric acid, oxalic acid, phosphoric acid, succinic acid, uric acid, an acidic ammonium salt such as ammonium chloride, or the like.
- the acid-activated gas-generating composition and the acid composition may each independently include one or more of: water; aloe vera extract; panthenol; a sugar, e.g. dextrose; an ionic surfactant, e.g., sodium lauryl sulfoacetate; a water soluble alkali metal halide salt, e.g., sodium chloride; a water soluble alkali earth metal salt, e.g., magnesium chloride; a nonionic surfactant, e.g., polyethylene oxide, a preservative, e.g., sodium benzoate; and sea trace elements.
- a sugar e.g. dextrose
- an ionic surfactant e.g., sodium lauryl sulfoacetate
- a water soluble alkali metal halide salt e.g., sodium chloride
- a water soluble alkali earth metal salt e.g., magnesium chloride
- the acid-activated gas-generating composition may include an acid-activated gas-generating agent such as sodium hydrogen carbonate as well as water, aloe vera extract, panthenol, dextrose, polyethylene oxide, sodium benzoate, sodium chloride, magnesium chloride, sodium lauryl sulfoacetate, dextrose, and sea trace elements.
- the acid composition may include an acid agent such as citric acid as well as water, aloe vera extract, panthenol, dextrose, polyethylene oxide, sodium benzoate, sodium chloride, magnesium chloride, and sea trace elements.
- the acid-activated gas-generating composition may include one or more of: a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, a sugar, or sea trace elements.
- the acid activated gas generating composition may include sodium hydrogen carbonate, a water soluble alkali metal halide salt, e.g., sodium chloride, a water soluble alkali earth metal salt, e.g., magnesium chloride; a sugar, e.g., dextrose; and sea trace elements.
- the acid composition may include citric acid, sodium chloride, magnesium chloride, dextrose, and sea trace elements.
- the acid-activated gas-generating composition may omit the sea trace elements.
- the acid composition may omit the sea trace elements.
- the method may include contacting the keratinized tissue with the acid-activated gas-generating composition causing a pH value of the keratinized tissue to be greater than about 7.
- Contacting the keratinized tissue with the acid composition may cause a pH value of the keratinized tissue to be less than about 7.
- At least one of the one or more treatment cycles may cause the keratinized tissue to vary in pH between an alkaline state and an acidic state.
- One or more of the acid-activated gas-generating composition and the acid composition may include a pH indicator.
- One or more of the acid-activated gas-generating composition and the acid composition collectively comprising an acidic pH indicator and an alkaline pH indicator.
- the keratinized tissue may include a plurality of cuticles. At least one of the one or more treatment cycles may include a pH value at the keratinized tissue effective to cause at least a portion of the plurality of cuticles to switch between an open state and a closed state.
- the keratinized tissue may include a plurality of keratinized epidermal skin cells. At least one of the one or more treatment cycles may cause a pH at the keratinized tissue to vary effective to cause at least a portion of the plurality of keratinized epidermal skin cells to be shed from the keratinized tissue.
- the method may include preparing the acid-activated gas-generating composition by contacting a precursor of the acid-activated gas-generating composition with one or more of: water or a slip composition.
- the method may include preparing the acid composition by contacting a precursor of the acid composition with one or more of: water or the slip composition.
- the slip composition may include one or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, or sea trace elements.
- a kit may be configured for treating a keratinized tissue condition in a subject in need thereof.
- the kit may include an acid-activated gas-generating composition or a precursor thereof included in a first reservoir.
- the kit may include an acid composition or a precursor thereof included in a second reservoir separated from the first reservoir.
- the kit may include instructions.
- the instructions may include directions to conduct one or more treatment cycles on the hair and/or skin. Each treatment cycle may include contacting the keratinized tissue with the acid-activated gas-generating composition. Each treatment cycle may include contacting the keratinized tissue with the acid composition.
- Each treatment cycle may include allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue.
- the first reservoir may include the precursor of the acid-activated gas-generating composition.
- the kit may also include a slip composition included in a third reservoir.
- the slip composition may include or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, a sugar, or sea trace elements.
- the kit may further include instructions to combine the slip composition with the precursor of the acid-activated gas-generating composition in the first reservoir to form the acid-activated gas-generating composition.
- the kit may include instructions to combine the slip composition with the precursor of the acid composition in the second reservoir to form the acid composition.
- the kit further comprising instructions to contact water to the precursor of the acid-activated gas-generating composition in the first reservoir.
- the kit may further include instructions to contact water to the precursor of the acid composition in the second reservoir.
- the instructions may include instructions for carrying out any method operation described herein.
- the instructions may direct a user to continue treating the keratinized tissue until the keratinized tissue condition may be at least partly ameliorated.
- the instructions may direct a user to treat a keratinized tissue condition including one or more of: acneiform eruptions, e.g., acne cosmetica, acne vulgaris , and the like; autoinflammatory syndromes, e.g., Blau syndrome, chronic infantile neurologic cutaneous and articular syndrome, and the like; chronic blistering, e.g., phemphigus conditions, and the like; conditions of the skin appendages, e.g., folliculitis, keratosis pilaris atrophicans, and the like; dermatitis, e.g., atopic dermatitis, contact dermatitis, eczema, pustular dermatitis, seborrheic dermatitis, and the like; drug or agent eruptions, e.g., penicillin allergy, nut allergy, poison oak or poison ivy, and the like; infection-related, e.g., bacterium-related, mycobacter
- the instructions may direct a user to treat a keratinized tissue including one or more of skin, hair, nails, scales, fur, or feathers.
- the instructions may direct a user to treat a keratinized tissue in a subject that may be a mammal, a bird, or a reptile.
- the subject may be a human.
- the instructions may direct a user to treat a keratinized tissue in at least one treatment cycle including contacting the keratinized tissue with the acid-activated gas-generating composition before contacting the keratinized tissue with the acid composition.
- the instructions may direct a user to treat a keratinized tissue in at least one treatment cycle including contacting the keratinized tissue with the acid composition before contacting the keratinized tissue with the acid-activated gas-generating composition.
- the instructions may direct a user to treat a keratinized tissue by conducting at least two or more of the treatment cycles in succession on the keratinized tissue.
- the instructions may direct a user to conduct at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more treatment cycles in a treatment session.
- the instructions may direct a user to treat a keratinized tissue in at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more treatment sessions of the treatment cycles described herein.
- the instructions may direct a user to treat a keratinized tissue by at least one treatment cycle including rinsing the keratinized tissue after allowing the acid composition and the acid-activated gas-generating composition to react effective to generate the gas at the keratinized tissue.
- the instructions may direct a user to treat a keratinized tissue by at least one treatment cycle including contacting the keratinized tissue with the acid composition after conducting the one or more treatment cycles on the keratinized tissue.
- the acid-activated gas-generating composition may include one or more gas generating agents, including one or more of: an alkali metal carbonate, alkali earth metal carbonate, an alkali metal bicarbonate, an alkali earth metal bicarbonate, or carbonic acid.
- alkali metals may include lithium, sodium, potassium, cesium, and the like.
- Alkali earth metals may include beryllium, magnesium, calcium, strontium, barium, and the like.
- the acid composition may include an acid including one or more of: lactic acid, acetic acid, formic acid, citric acid, oxalic acid, phosphoric acid, succinic acid, uric acid, or an acidic ammonium salt.
- the acid composition may include an acid comprising one or more of: lactic acid, acetic acid, formic acid, citric acid, oxalic acid, phosphoric acid, succinic acid, uric acid, an acidic ammonium salt such as ammonium chloride, or the like.
- the acid-activated gas-generating composition and the acid composition may each independently include one or more of: water; aloe vera extract; panthenol; a sugar, e.g. dextrose; an ionic surfactant, e.g., sodium lauryl sulfoacetate; a water soluble alkali metal halide salt, e.g., sodium chloride; a water soluble alkali earth metal salt, e.g., magnesium chloride; a nonionic surfactant, e.g., polyethylene oxide, a preservative, e.g., sodium benzoate; and sea trace elements.
- a sugar e.g. dextrose
- an ionic surfactant e.g., sodium lauryl sulfoacetate
- a water soluble alkali metal halide salt e.g., sodium chloride
- a water soluble alkali earth metal salt e.g., magnesium chloride
- the acid-activated gas-generating composition may include an acid-activated gas-generating agent such as sodium hydrogen carbonate as well as water, aloe vera extract, panthenol, dextrose, polyethylene oxide, sodium benzoate, sodium chloride, magnesium chloride, sodium lauryl sulfoacetate, dextrose, and sea trace elements.
- the acid composition may include an acid agent such as citric acid as well as water, aloe vera extract, panthenol, dextrose, polyethylene oxide, sodium benzoate, sodium chloride, magnesium chloride, and sea trace elements.
- the acid activated gas generating composition may include sodium hydrogen carbonate, a water soluble alkali metal halide salt, e.g., sodium chloride, a water soluble alkali earth metal salt, e.g., magnesium chloride; a sugar, e.g., dextrose; and sea trace elements.
- the acid composition may include citric acid, sodium chloride, magnesium chloride, dextrose, and sea trace elements.
- one or more of the acid-activated gas-generating composition and the acid composition may include a pH indicator.
- one or more of the acid-activated gas-generating composition and the acid composition may collectively include an acidic pH indicator and an alkaline pH indicator.
- the instructions may direct a user to treat a keratinized tissue by adjusting the keratinized tissue to between a pH of about 4.5 and a pH of about 6.5 after conducting the one or more treatment cycles on the keratinized tissue.
- the instructions may direct a user to contact the keratinized tissue with the acid-activated gas-generating composition effective to cause a pH value of the keratinized tissue to be greater than about 7.
- the instructions may direct a user to contact the keratinized tissue with the acid composition causing a pH value of the keratinized tissue to be less than about 7.
- the instructions may direct a user to conduct at least one of the one or more treatment cycles effective to cause the keratinized tissue to vary in pH between an alkaline state and an acidic state.
- the instructions may direct a user to conduct at least one of the one or more treatment cycles varying a pH value at the keratinized tissue effective to cause at least a portion of a plurality of cuticles of the keratinized tissue to switch between an open state and a closed state.
- the instructions may direct a user to conduct at least one of the one or more treatment cycles causing a pH at the keratinized tissue to vary effective to cause at least a portion of a plurality of keratinized epidermal skin cells to be shed from the keratinized tissue.
- a 53 year old Caucasian female presented with a medium fine hair in a relatively thick density at the subject's scalp. Prior to treatment, the subject complained of a very tight-feeling and itchy, dry scalp. Multiple areas of flaking dry dandruff were observed on the scalp and visible dandruff was observed on the subject's clothing, mostly in the shoulder area. Visible, reddish pink irritations were observed on the scalp in multiple areas. Dandruff was observed to be scattered throughout the scalp, at areas of the reddish pink irritations and at apparently non-irritated areas. Some of the irritations appeared circular in nature with the center of the circle appearing unaffected, or less affected; while no specific diagnosis was made, this circular irritation model is consistent with various fungal infections.
- compositions are Compositions:
- An acid-activated gas-generating composition was prepared in a first squirt bottle by adding 20 mL of a Slip composition and warm tap water (XX mL).
- the Slip composition included water, Aloe Vera Extract ( Aloe Barbensis leaf extract), panthenol, (Panthothenic acid (Vitamin B5)), dextrose, polyethylene oxide, and sodium benzoate. [Marty, we need composition proportions or a commercial source for the Slip composition].
- the first squirt bottle also contained sodium hydrogen carbonate, sodium chloride, magnesium chloride, sodium lauryl sulfoacetate, dextrose, and sea trace elements. [Marty, we need composition proportions]
- the combined contents of the first squirt bottle were mixed by shaking to form a uniform solution of the acid-activated gas-generating composition, which had an alkaline pH.
- An acid composition was prepared in a second squirt bottle by adding 20 mL of a Slip composition and warm tap water (XX mL).
- the Slip composition included water, Aloe Vera Extract ( Aloe Barbensis leaf extract), panthenol, (Panthothenic acid (Vitamin B5)), dextrose, polyethylene oxide, and sodium benzoate. [Marty, we need composition proportions or a commercial source for the Slip composition].
- the second squirt bottle also contained citric acid, sodium chloride, magnesium chloride, dextrose, and sea trace elements. [Marty, we need composition proportions]
- the combined contents of the second squirt bottle were mixed by shaking to form a uniform solution of the acid composition, which had an acidic pH.
- the subject's hair and scalp was first washed with a conventional hydrating shampoo according to the manufacturer's directions. Subsequently, a treatment cycle was performed by contacting the subject's hair and scalp sequentially with roughly equal volumes of the acid-activated gas-generating composition and the acid composition. Contacting the acid-activated gas-generating composition with the acid composition led to rapid gas generation and bubbling at the hair/scalp, which the subject experienced as a refreshing tingling sensation.
- the treatment cycle was repeated about 10 more times, ending with the acid composition to give the hair and scalp an acidic pH.
- the subject's hair and scalp were then rinsed well with warm water.
- a conventional hair conditioner was applied and rinsed according to the manufacturer's directions. The subject's hair was then dried. The preceding steps were repeated 3 more times over a two-week period totaling four treatment sessions.
- Seborrheic eczema is also very common in humans. Conditions such as Tinea Capitis may be caused or exacerbated by fungus and yeast. Seborrheic Eczema may be caused, exacerbated, or associated with the overproduction of oil by the scalp.
- the yeast Malassezia formerly Pityrosporum , is a fungi genus believed to be the cause of many cases of dandruff and seborrhoeic dermatitis.
- the yeast Malassezia is common on the human scalp because it requires lipids to grow and is observed to be concentrated near the sebaceous glands of the scalp. When a skin infection due to fungi and/or bacteria grows rapidly, it is believed that the natural renewal of skin cells may be disturbed and dandruff and itching may occur. In the case of Malassezia , lipases and phospholipases are employed to metabolize and break down lipids found in the oils of the scalp. Malassezia is a facultative anaerobe and may grow best in the presence of oxygen, but does not require oxygen.
- treatment according to the present example may create a less favorable environment for the yeast, such that fewer numbers should be reproduced in a given period of time compared to untreated hair and scalp which may reduce the occurrence of dandruff.
- the carbon dioxide evolved may decrease local oxygen concentrations and impair yeast growth.
- the surfactant Sodium Lauryl Sulfoacetate employed in the acid-activated gas-generating composition may have reduced the amount of oil on the scalp and hair, perhaps “starving” the remaining yeast of necessary nutrients for reproduction and cellular metabolism.
- the stimulation to the scalp provided by the gas evolution may increase the blood supply and may loosen and help remove dead skin cells.
- a 67 year old Caucasian male presented with a physician's diagnosis of psoriasis on many parts of his body including the palms of his hands.
- the subject complained that his hands are treated with painful steroid injections into the palms of his hands by his dermatologist once a week.
- the sites on the hands were observed with open wounds where the underlying tissue was exposed and was weeping slightly.
- the sites on the subject's hands were observed with a dark purple coloration and dead skin scaling off of the surface.
- the subject explained that the sites burn severely and worse with the contact of hot water.
- the subject also reported being self-conscious of his hands to the point that he avoids shaking people's hands.
- the subject reported trouble sleeping at night due to the pain experienced in his hands.
- the subject reported application of hand lotion to try to hydrate his hands, but with aggravation of the affected areas and with an undesirable “stinging” sensation.
- compositions are Compositions:
- the acid-activated gas-generating composition and acid composition were prepared as described in EXAMPLE 1, except that sodium lauryl sulfoacetate was not present to avoid further drying of the subject's hands.
- the subject's hands were treated with 10 consecutive treatment cycles, constituting a treatment session, each cycle beginning with the acid-activated gas-generating composition and ending with the acid composition to leave the skin at an acidic pH.
- the subject received at least three treatment sessions per week over a three month period.
- the subject reported cessation of the steroid injections as a result of the treatment described above. Further, the subject's hands were observed to have educed flaking skin and the absence of open lesions; improved skin color, with reduced purple and grey coloration. The subject reported cessation of pain, itching, and burning as a result of the treatment sessions. The subject reported increased self-confidence and well-being due to the improvement to his hands. The subject reported a normal routine of bathing and hand washing.
- compositions are Compositions:
- the acid-activated gas-generating composition and acid composition were prepared as described in EXAMPLE 1.
- the subject's hair and scalp was first washed with a conventional hydrating shampoo according to the manufacturer's directions. Subsequently, a treatment session including 10 treatment cycles was performed, each treatment cycle conducted by contacting the subject's hair and scalp sequentially with roughly equal volumes of the acid-activated gas-generating composition and the acid composition. Contacting the acid-activated gas-generating composition with the acid composition led to rapid gas generation and bubbling at the hair/scalp, which the subject experienced as a refreshing tingling sensation. Each treatment cycle caused the pH at the hair and scalp to cycle between alkaline and acid. After a period of several weeks, the subject returned and a second treatment session was conducted. Subsequently, further treatment sessions were conducted every five weeks for a period of several months.
- the subject's hair and scalp was examined. Compared to before the two treatment sessions, the subject's scalp was 95% free of dandruff. Very little physical appearance of dandruff was observed. The subject reported that the dryness, tight scalp and itching was ameliorated over the course of the two treatment sessions. Moreover, the subject reported that the dandruff was ameliorated after the first treatment session and was dandruff-free up to the second treatment session. The subject reported that she has never been this dandruff-free in her whole adult life, despite trying numerous shampoos and conditioners that claim to help with removing dandruff.
- the term “about” in conjunction with a number is intended to include ⁇ 10% of the number. In other words, “about 10” may mean from 9 to 11.
- the terms “optional” and “optionally” mean that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.
- substituted refers to an organic group as defined below (e.g., an alkyl group) in which one or more bonds to a hydrogen atom contained therein may be replaced by a bond to non-hydrogen or non-carbon atoms.
- Substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom may be replaced by one or more bonds, including double or triple bonds, to a heteroatom.
- a substituted group may be substituted with one or more substituents, unless otherwise specified. In some embodiments, a substituted group may be substituted with 1, 2, 3, 4, 5, or 6 substituents.
- substituent groups include: halogens (e.g., F, Cl, Br, and I); hydroxyls; alkoxy, alkenoxy, aryloxy, aralkyloxy, heterocyclyloxy, and heterocyclylalkoxy groups; carbonyls (oxo); carboxyls; esters; urethanes; oximes; hydroxylamines; alkoxyamines; aralkoxyamines; thiols; sulfides; sulfoxides; sulfones; sulfonyls; sulfonamides; amines; N-oxides; hydrazines; hydrazides; hydrazones; azides; amides; ureas; amidines; guanidines; enamines; imides; isocyanates; isothiocyanates; cyanates; thiocyanates; imines; nitro groups; or nitriles.
- halogens
- a “per”-substituted compound or group is a compound or group having all or substantially all substitutable positions substituted with the indicated substituent.
- 1,6-diiodo perfluoro hexane indicates a compound of formula C 6 F 12 I 2 , where all the substitutable hydrogens have been replaced with fluorine atoms.
- Substituted ring groups such as substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups also include rings and ring systems in which a bond to a hydrogen atom may be replaced with a bond to a carbon atom.
- Substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups may also be substituted with substituted or unsubstituted alkyl, alkenyl, and alkynyl groups as defined below.
- Alkyl groups include straight chain and branched chain alkyl groups having from 1 to 12 carbon atoms, and typically from 1 to 10 carbons or, in some examples, from 1 to 8, 1 to 6, or 1 to 4 carbon atoms.
- straight chain alkyl groups include groups such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups.
- branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, tert-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups.
- Representative substituted alkyl groups may be substituted one or more times with substituents such as those listed above and include, without limitation, haloalkyl (e.g., trifluoromethyl), hydroxyalkyl, thioalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, or carboxyalkyl.
- Cycloalkyl groups include mono-, bi- or tricyclic alkyl groups having from 3 to 12 carbon atoms in the ring(s), or, in some embodiments, 3 to 10, 3 to 8, or 3 to 4, 5, or 6 carbon atoms.
- Exemplary monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.
- the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments, the number of ring carbon atoms ranges from 3 to 5, 3 to 6, or 3 to 7.
- Bi- and tricyclic ring systems include both bridged cycloalkyl groups and fused rings, such as, but not limited to, bicyclo[2.1.1]hexane, adamantyl, or decalinyl.
- Substituted cycloalkyl groups may be substituted one or more times with non-hydrogen and non-carbon groups as defined above.
- substituted cycloalkyl groups also include rings that may be substituted with straight or branched chain alkyl groups as defined above.
- Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4-2,5- or 2,6-disubstituted cyclohexyl groups, which may be substituted with substituents such as those listed above.
- Aryl groups may be cyclic aromatic hydrocarbons that do not contain heteroatoms.
- Aryl groups herein include monocyclic, bicyclic and tricyclic ring systems.
- Aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, fluorenyl, phenanthrenyl, anthracenyl, indenyl, indanyl, pentalenyl, and naphthyl groups.
- aryl groups contain 6-14 carbons, and in others from 6 to 12 or even 6-10 carbon atoms in the ring portions of the groups.
- the aryl groups may be phenyl or naphthyl.
- aryl groups may include groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl or tetrahydronaphthyl), “aryl groups” does not include aryl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members. Rather, groups such as tolyl may be referred to as substituted aryl groups. Representative substituted aryl groups may be mono-substituted or substituted more than once. For example, monosubstituted aryl groups include, but are not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl, which may be substituted with substituents such as those above.
- Aralkyl groups may be alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group may be replaced with a bond to an aryl group as defined above.
- aralkyl groups contain 7 to 16 carbon atoms, 7 to 14 carbon atoms, or 7 to 10 carbon atoms.
- Substituted aralkyl groups may be substituted at the alkyl, the aryl or both the alkyl and aryl portions of the group.
- Representative aralkyl groups include but are not limited to benzyl and phenethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-indanylethyl. Substituted aralkyls may be substituted one or more times with substituents as listed above.
- Groups described herein having two or more points of attachment may be designated by use of the suffix, “ene.”
- divalent alkyl groups may be alkylene groups
- divalent aryl groups may be arylene groups
- divalent heteroaryl groups may be heteroarylene groups, and so forth.
- certain polymers may be described by use of the suffix “ene” in conjunction with a term describing the polymer repeat unit.
- Alkoxy groups may be hydroxyl groups (—OH) in which the bond to the hydrogen atom may be replaced by a bond to a carbon atom of a substituted or unsubstituted alkyl group as defined above.
- linear alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy.
- branched alkoxy groups include, but are not limited to, isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, or isohexoxy.
- cycloalkoxy groups include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, or cyclohexyloxy.
- Representative substituted alkoxy groups may be substituted one or more times with substituents such as those listed above.
- amine refers to NR 5 R 6 groups, wherein R 5 and R 6 may be independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
- the amine may be alkylamino, dialkylamino, arylamino, or alkylarylamino.
- the amine may be NH 2 , methylamino, dimethylamino, ethylamino, diethylamino, propylamino, isopropylamino, phenylamino, or benzylamino.
- alkylamino may be defined as NR 7 R 8 , wherein at least one of R 7 and R 8 may be alkyl and the other may be alkyl or hydrogen.
- arylamino may be defined as NR 9 R 10 , wherein at least one of R 9 and R 10 may be aryl and the other may be aryl or hydrogen.
- halogen refers to bromine, chlorine, fluorine, or iodine. In some embodiments, the halogen may be fluorine. In other embodiments, the halogen may be chlorine or bromine.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Described are methods and kits for treating a keratinized tissue condition in a subject in need thereof. The method may include conducting one or more treatment cycles on the keratinized tissue. Each treatment cycle may include contacting the keratinized tissue with an acid-activated gas-generating composition. Each treatment cycle may include contacting the keratinized tissue with an acid composition. Each treatment cycle may include allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue.
Description
- Keratinized tissues such as hair, skin, nails, fur, feathers, and the like may exhibit a variety of conditions which may have cosmetic or health implications. For example, hair may become dull, stiff, oily, easily tangled, easily frayed and the like as a result of environmental factors, endogenous health conditions, or other factors. Likewise, keratin on the surface of skin may become irritated, scaly, rough, and the like, again as a result of environmental factors, endogenous health conditions, or other factors. Areas of high skin/hair interface, such as at the scalp, may present additional issues, such as dandruff. Similar issues may affect skin, claws, fur, and feathers of nonhuman animals. Although many treatments exist to treat various conditions of keratinized tissues such treatments may suffer from issues of cost, lack of efficacy, lack of efficacy for multiple related conditions across both skin and hair, requirement for prescription, harsh, irritating, or dangerous chemicals, and the like.
- The present disclosure appreciates that ameliorating various conditions of keratinized tissues may be a challenging endeavor.
- In various embodiments, a method is provided for treating a keratinized tissue condition in a subject in need thereof. The method may include conducting one or more treatment cycles on the keratinized tissue. Each treatment cycle may include contacting the keratinized tissue with an acid-activated gas-generating composition. Each treatment cycle may include contacting the keratinized tissue with an acid composition. Each treatment cycle may include allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue.
- In various embodiments, a kit is provided. The kit may be configured for treating a keratinized tissue condition in a subject in need thereof. The kit may include an acid-activated gas-generating composition or a precursor thereof included in a first reservoir. The kit may include an acid composition or a precursor thereof included in a second reservoir separated from the first reservoir. The kit may include instructions. The instructions may include directions to conduct one or more treatment cycles on the hair and/or skin. Each treatment cycle may include contacting the keratinized tissue with the acid-activated gas-generating composition. Each treatment cycle may include contacting the keratinized tissue with the acid composition. Each treatment cycle may include allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue.
- The accompanying figures, which are incorporated in and constitute a part of the specification, illustrate example methods and apparatuses, and are used merely to illustrate example embodiments.
-
FIG. 1 depicts a flow chart of a method 100 for treating a keratinized tissue condition in a subject in need thereof. - In various embodiments, a method 100 is provided for treating a keratinized tissue condition in a subject in need thereof.
FIG. 1 depicts a flow chart of a method 100. Method 100 may include 102 conducting one or more treatment cycles on the keratinized tissue. Each treatment cycle may include 104 contacting the keratinized tissue with an acid-activated gas-generating composition. Each treatment cycle may include 106 contacting the keratinized tissue with an acid composition. Each treatment cycle may include 108 allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue. - In some embodiments, the keratinized tissue condition may be at least partly ameliorated. The keratinized tissue condition may include one or more of, for example: acneiform eruptions, e.g., acne cosmetica, acne vulgaris, and the like; autoinflammatory syndromes, e.g., Blau syndrome, chronic infantile neurologic cutaneous and articular syndrome, and the like; chronic blistering, e.g., phemphigus conditions, and the like; conditions of the skin appendages, e.g., folliculitis, keratosis pilaris atrophicans, and the like; dermatitis, e.g., atopic dermatitis, contact dermatitis, eczema, pustular dermatitis, seborrheic dermatitis, and the like; drug or agent eruptions, e.g., penicillin allergy, nut allergy, poison oak or poison ivy, and the like; infection-related, e.g., bacterium-related, mycobacterium-related, mycosis-related, parasitic infestations, stings, and bites, virus-related, lichenoid eruptions, and the like; papulosquamous hyperkeratosis, palmoplantar keratodermas, pruritis, e.g., itching or other sensation, and the like; psoriasis, resulting from physical factors, e.g., blisters, chapping, and the like; ionizing radiation-induced, e.g., radiation induced acne, radiodermatitis, and the like. The keratinized tissue may include one or more of skin, hair, nails, scales, fur, or feathers. The subject may be a mammal, a bird, or a reptile. For example, the subject may be a human.
- In several embodiments, at least one treatment cycle may include contacting the keratinized tissue with the acid-activated gas-generating composition before contacting the keratinized tissue with the acid composition. Additionally or alternatively, at least one treatment cycle may include contacting the keratinized tissue with the acid composition before contacting the keratinized tissue with the acid-activated gas-generating composition. The method may also include conducting two or more of the treatment cycles in succession on the keratinized tissue. Additionally or alternatively, at least one treatment cycle may include rinsing the keratinized tissue after allowing the acid composition and the acid-activated gas-generating composition to react effective to generate the gas at the keratinized tissue. Additionally or alternatively, at least one treatment cycle comprising contacting the keratinized tissue with the acid composition after conducting the one or more treatment cycles on the keratinized tissue.
- In various embodiments, the method may include adjusting the keratinized tissue to between a pH of about 4.5 and a pH of about 6.5 after conducting the one or more treatment cycles on the keratinized tissue. The method may include adjusting the keratinized tissue to between a pH of about 4.5 and a pH of about 5.5 after conducting the one or more treatment cycles on the keratinized tissue.
- In some embodiments, the acid-activated gas-generating composition may include one or more gas generating agents, including one or more of: an alkali metal carbonate, alkali earth metal carbonate, an alkali metal bicarbonate, an alkali earth metal bicarbonate, or carbonic acid. For example, alkali metals may include lithium, sodium, potassium, cesium, and the like. Alkali earth metals may include beryllium, magnesium, calcium, strontium, barium, and the like. The acid composition may include an acid including one or more of: lactic acid, acetic acid, formic acid, citric acid, oxalic acid, phosphoric acid, succinic acid, uric acid, an acidic ammonium salt such as ammonium chloride, or the like.
- In several embodiments, the acid-activated gas-generating composition and the acid composition may each independently include one or more of: water; aloe vera extract; panthenol; a sugar, e.g. dextrose; an ionic surfactant, e.g., sodium lauryl sulfoacetate; a water soluble alkali metal halide salt, e.g., sodium chloride; a water soluble alkali earth metal salt, e.g., magnesium chloride; a nonionic surfactant, e.g., polyethylene oxide, a preservative, e.g., sodium benzoate; and sea trace elements. For example, the acid-activated gas-generating composition may include an acid-activated gas-generating agent such as sodium hydrogen carbonate as well as water, aloe vera extract, panthenol, dextrose, polyethylene oxide, sodium benzoate, sodium chloride, magnesium chloride, sodium lauryl sulfoacetate, dextrose, and sea trace elements. Further, for example, the acid composition may include an acid agent such as citric acid as well as water, aloe vera extract, panthenol, dextrose, polyethylene oxide, sodium benzoate, sodium chloride, magnesium chloride, and sea trace elements. The acid-activated gas-generating composition may include one or more of: a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, a sugar, or sea trace elements. The acid activated gas generating composition may include sodium hydrogen carbonate, a water soluble alkali metal halide salt, e.g., sodium chloride, a water soluble alkali earth metal salt, e.g., magnesium chloride; a sugar, e.g., dextrose; and sea trace elements. The acid composition may include citric acid, sodium chloride, magnesium chloride, dextrose, and sea trace elements. In various embodiments, the acid-activated gas-generating composition may omit the sea trace elements. The acid composition may omit the sea trace elements.
- In various embodiments, the method may include contacting the keratinized tissue with the acid-activated gas-generating composition causing a pH value of the keratinized tissue to be greater than about 7. Contacting the keratinized tissue with the acid composition may cause a pH value of the keratinized tissue to be less than about 7. At least one of the one or more treatment cycles may cause the keratinized tissue to vary in pH between an alkaline state and an acidic state. One or more of the acid-activated gas-generating composition and the acid composition may include a pH indicator. One or more of the acid-activated gas-generating composition and the acid composition collectively comprising an acidic pH indicator and an alkaline pH indicator.
- In some embodiments, the keratinized tissue may include a plurality of cuticles. At least one of the one or more treatment cycles may include a pH value at the keratinized tissue effective to cause at least a portion of the plurality of cuticles to switch between an open state and a closed state. The keratinized tissue may include a plurality of keratinized epidermal skin cells. At least one of the one or more treatment cycles may cause a pH at the keratinized tissue to vary effective to cause at least a portion of the plurality of keratinized epidermal skin cells to be shed from the keratinized tissue.
- In several embodiments, the method may include preparing the acid-activated gas-generating composition by contacting a precursor of the acid-activated gas-generating composition with one or more of: water or a slip composition. The method may include preparing the acid composition by contacting a precursor of the acid composition with one or more of: water or the slip composition. The slip composition may include one or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, or sea trace elements.
- In various embodiments, a kit is provided. The kit may be configured for treating a keratinized tissue condition in a subject in need thereof. The kit may include an acid-activated gas-generating composition or a precursor thereof included in a first reservoir. The kit may include an acid composition or a precursor thereof included in a second reservoir separated from the first reservoir. The kit may include instructions. The instructions may include directions to conduct one or more treatment cycles on the hair and/or skin. Each treatment cycle may include contacting the keratinized tissue with the acid-activated gas-generating composition. Each treatment cycle may include contacting the keratinized tissue with the acid composition. Each treatment cycle may include allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue.
- In some embodiments, the first reservoir may include the precursor of the acid-activated gas-generating composition. The kit may also include a slip composition included in a third reservoir. The slip composition may include or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, a sugar, or sea trace elements. The kit may further include instructions to combine the slip composition with the precursor of the acid-activated gas-generating composition in the first reservoir to form the acid-activated gas-generating composition. Alternatively or in addition, the kit may include instructions to combine the slip composition with the precursor of the acid composition in the second reservoir to form the acid composition.
- In various embodiments, the kit further comprising instructions to contact water to the precursor of the acid-activated gas-generating composition in the first reservoir. The kit may further include instructions to contact water to the precursor of the acid composition in the second reservoir.
- In several embodiments, the instructions may include instructions for carrying out any method operation described herein. For example, the instructions may direct a user to continue treating the keratinized tissue until the keratinized tissue condition may be at least partly ameliorated.
- In various embodiments, the instructions may direct a user to treat a keratinized tissue condition including one or more of: acneiform eruptions, e.g., acne cosmetica, acne vulgaris, and the like; autoinflammatory syndromes, e.g., Blau syndrome, chronic infantile neurologic cutaneous and articular syndrome, and the like; chronic blistering, e.g., phemphigus conditions, and the like; conditions of the skin appendages, e.g., folliculitis, keratosis pilaris atrophicans, and the like; dermatitis, e.g., atopic dermatitis, contact dermatitis, eczema, pustular dermatitis, seborrheic dermatitis, and the like; drug or agent eruptions, e.g., penicillin allergy, nut allergy, poison oak or poison ivy, and the like; infection-related, e.g., bacterium-related, mycobacterium-related, mycosis-related, parasitic infestations, stings, and bites, virus-related, lichenoid eruptions, and the like; papulosquamous hyperkeratosis; palmoplantar keratodermas; pruritis, e.g., itching or other sensation, and the like; psoriasis, resulting from physical factors, e.g., blisters, chapping, and the like; ionizing radiation-induced, e.g., radiation induced acne, radiodermatitis, and the like;
- In some embodiments, the instructions may direct a user to treat a keratinized tissue including one or more of skin, hair, nails, scales, fur, or feathers. The instructions may direct a user to treat a keratinized tissue in a subject that may be a mammal, a bird, or a reptile. For example, the subject may be a human.
- In several embodiments, the instructions may direct a user to treat a keratinized tissue in at least one treatment cycle including contacting the keratinized tissue with the acid-activated gas-generating composition before contacting the keratinized tissue with the acid composition. The instructions may direct a user to treat a keratinized tissue in at least one treatment cycle including contacting the keratinized tissue with the acid composition before contacting the keratinized tissue with the acid-activated gas-generating composition. The instructions may direct a user to treat a keratinized tissue by conducting at least two or more of the treatment cycles in succession on the keratinized tissue. For example, the instructions may direct a user to conduct at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more treatment cycles in a treatment session. The instructions may direct a user to treat a keratinized tissue in at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more treatment sessions of the treatment cycles described herein. The instructions may direct a user to treat a keratinized tissue by at least one treatment cycle including rinsing the keratinized tissue after allowing the acid composition and the acid-activated gas-generating composition to react effective to generate the gas at the keratinized tissue. The instructions may direct a user to treat a keratinized tissue by at least one treatment cycle including contacting the keratinized tissue with the acid composition after conducting the one or more treatment cycles on the keratinized tissue.
- In various embodiments, in the kit, the acid-activated gas-generating composition may include one or more gas generating agents, including one or more of: an alkali metal carbonate, alkali earth metal carbonate, an alkali metal bicarbonate, an alkali earth metal bicarbonate, or carbonic acid. For example, alkali metals may include lithium, sodium, potassium, cesium, and the like. Alkali earth metals may include beryllium, magnesium, calcium, strontium, barium, and the like.
- In some embodiments, in the kit, the acid composition may include an acid including one or more of: lactic acid, acetic acid, formic acid, citric acid, oxalic acid, phosphoric acid, succinic acid, uric acid, or an acidic ammonium salt. The acid composition may include an acid comprising one or more of: lactic acid, acetic acid, formic acid, citric acid, oxalic acid, phosphoric acid, succinic acid, uric acid, an acidic ammonium salt such as ammonium chloride, or the like.
- In several embodiments, in the kit, the acid-activated gas-generating composition and the acid composition may each independently include one or more of: water; aloe vera extract; panthenol; a sugar, e.g. dextrose; an ionic surfactant, e.g., sodium lauryl sulfoacetate; a water soluble alkali metal halide salt, e.g., sodium chloride; a water soluble alkali earth metal salt, e.g., magnesium chloride; a nonionic surfactant, e.g., polyethylene oxide, a preservative, e.g., sodium benzoate; and sea trace elements. For example, the acid-activated gas-generating composition may include an acid-activated gas-generating agent such as sodium hydrogen carbonate as well as water, aloe vera extract, panthenol, dextrose, polyethylene oxide, sodium benzoate, sodium chloride, magnesium chloride, sodium lauryl sulfoacetate, dextrose, and sea trace elements. Further, for example, the acid composition may include an acid agent such as citric acid as well as water, aloe vera extract, panthenol, dextrose, polyethylene oxide, sodium benzoate, sodium chloride, magnesium chloride, and sea trace elements. In the kit, the acid activated gas generating composition may include sodium hydrogen carbonate, a water soluble alkali metal halide salt, e.g., sodium chloride, a water soluble alkali earth metal salt, e.g., magnesium chloride; a sugar, e.g., dextrose; and sea trace elements. In the kit, the acid composition may include citric acid, sodium chloride, magnesium chloride, dextrose, and sea trace elements.
- In various embodiments, in the kit, one or more of the acid-activated gas-generating composition and the acid composition may include a pH indicator. For example, one or more of the acid-activated gas-generating composition and the acid composition may collectively include an acidic pH indicator and an alkaline pH indicator. The instructions may direct a user to treat a keratinized tissue by adjusting the keratinized tissue to between a pH of about 4.5 and a pH of about 6.5 after conducting the one or more treatment cycles on the keratinized tissue. The instructions may direct a user to contact the keratinized tissue with the acid-activated gas-generating composition effective to cause a pH value of the keratinized tissue to be greater than about 7. The instructions may direct a user to contact the keratinized tissue with the acid composition causing a pH value of the keratinized tissue to be less than about 7. The instructions may direct a user to conduct at least one of the one or more treatment cycles effective to cause the keratinized tissue to vary in pH between an alkaline state and an acidic state. The instructions may direct a user to conduct at least one of the one or more treatment cycles varying a pH value at the keratinized tissue effective to cause at least a portion of a plurality of cuticles of the keratinized tissue to switch between an open state and a closed state. The instructions may direct a user to conduct at least one of the one or more treatment cycles causing a pH at the keratinized tissue to vary effective to cause at least a portion of a plurality of keratinized epidermal skin cells to be shed from the keratinized tissue.
- Observed Condition Prior to Treatment:
- A 53 year old Caucasian female presented with a medium fine hair in a relatively thick density at the subject's scalp. Prior to treatment, the subject complained of a very tight-feeling and itchy, dry scalp. Multiple areas of flaking dry dandruff were observed on the scalp and visible dandruff was observed on the subject's clothing, mostly in the shoulder area. Visible, reddish pink irritations were observed on the scalp in multiple areas. Dandruff was observed to be scattered throughout the scalp, at areas of the reddish pink irritations and at apparently non-irritated areas. Some of the irritations appeared circular in nature with the center of the circle appearing unaffected, or less affected; while no specific diagnosis was made, this circular irritation model is consistent with various fungal infections. Other areas of solid irritations were observed to be approximately 0.5 to 1.5 cm in size. A physician commented on the preceding description and suggested the subject could have been suffering from Tinea Capitis or ringworm of the scalp, a fungal infection, and/or seborrheic eczema.
- Compositions:
- An acid-activated gas-generating composition was prepared in a first squirt bottle by adding 20 mL of a Slip composition and warm tap water (XX mL). The Slip composition included water, Aloe Vera Extract (Aloe Barbensis leaf extract), panthenol, (Panthothenic acid (Vitamin B5)), dextrose, polyethylene oxide, and sodium benzoate. [Marty, we need composition proportions or a commercial source for the Slip composition]. The first squirt bottle also contained sodium hydrogen carbonate, sodium chloride, magnesium chloride, sodium lauryl sulfoacetate, dextrose, and sea trace elements. [Marty, we need composition proportions] The combined contents of the first squirt bottle were mixed by shaking to form a uniform solution of the acid-activated gas-generating composition, which had an alkaline pH.
- An acid composition was prepared in a second squirt bottle by adding 20 mL of a Slip composition and warm tap water (XX mL). The Slip composition included water, Aloe Vera Extract (Aloe Barbensis leaf extract), panthenol, (Panthothenic acid (Vitamin B5)), dextrose, polyethylene oxide, and sodium benzoate. [Marty, we need composition proportions or a commercial source for the Slip composition]. The second squirt bottle also contained citric acid, sodium chloride, magnesium chloride, dextrose, and sea trace elements. [Marty, we need composition proportions] The combined contents of the second squirt bottle were mixed by shaking to form a uniform solution of the acid composition, which had an acidic pH.
- Treatment:
- The subject's hair and scalp was first washed with a conventional hydrating shampoo according to the manufacturer's directions. Subsequently, a treatment cycle was performed by contacting the subject's hair and scalp sequentially with roughly equal volumes of the acid-activated gas-generating composition and the acid composition. Contacting the acid-activated gas-generating composition with the acid composition led to rapid gas generation and bubbling at the hair/scalp, which the subject experienced as a refreshing tingling sensation. The treatment cycle was repeated about 10 more times, ending with the acid composition to give the hair and scalp an acidic pH. The subject's hair and scalp were then rinsed well with warm water. A conventional hair conditioner was applied and rinsed according to the manufacturer's directions. The subject's hair was then dried. The preceding steps were repeated 3 more times over a two-week period totaling four treatment sessions.
- Results:
- After the four treatment sessions, the subject's hair and scalp was examined. No signs of dandruff or reddish irritations were observed on the subject's scalp. The subject reported that the dryness, tight scalp and itching was ameliorated over the course of the four treatment sessions.
- Discussion:
- Without wishing to be bound by theory, possible reasons for changes on the subject's hair and scalp are presented. Humans may display some form of dandruff throughout their lives and at many different times. Seborrheic eczema is also very common in humans. Conditions such as Tinea Capitis may be caused or exacerbated by fungus and yeast. Seborrheic Eczema may be caused, exacerbated, or associated with the overproduction of oil by the scalp. The yeast Malassezia, formerly Pityrosporum, is a fungi genus believed to be the cause of many cases of dandruff and seborrhoeic dermatitis. The yeast Malassezia is common on the human scalp because it requires lipids to grow and is observed to be concentrated near the sebaceous glands of the scalp. When a skin infection due to fungi and/or bacteria grows rapidly, it is believed that the natural renewal of skin cells may be disturbed and dandruff and itching may occur. In the case of Malassezia, lipases and phospholipases are employed to metabolize and break down lipids found in the oils of the scalp. Malassezia is a facultative anaerobe and may grow best in the presence of oxygen, but does not require oxygen. It is believed that treatment according to the present example may create a less favorable environment for the yeast, such that fewer numbers should be reproduced in a given period of time compared to untreated hair and scalp which may reduce the occurrence of dandruff. The carbon dioxide evolved may decrease local oxygen concentrations and impair yeast growth. Further, the surfactant (Sodium Lauryl Sulfoacetate) employed in the acid-activated gas-generating composition may have reduced the amount of oil on the scalp and hair, perhaps “starving” the remaining yeast of necessary nutrients for reproduction and cellular metabolism. Also, the stimulation to the scalp provided by the gas evolution may increase the blood supply and may loosen and help remove dead skin cells.
- Observed Condition Prior to Treatment:
- A 67 year old Caucasian male presented with a physician's diagnosis of psoriasis on many parts of his body including the palms of his hands. The subject complained that his hands are treated with painful steroid injections into the palms of his hands by his dermatologist once a week. The sites on the hands were observed with open wounds where the underlying tissue was exposed and was weeping slightly. The sites on the subject's hands were observed with a dark purple coloration and dead skin scaling off of the surface. The subject explained that the sites burn terribly and worse with the contact of hot water. The subject also reported being self-conscious of his hands to the point that he avoids shaking people's hands. The subject reported trouble sleeping at night due to the pain experienced in his hands. The subject reported application of hand lotion to try to hydrate his hands, but with aggravation of the affected areas and with an undesirable “stinging” sensation.
- Compositions:
- The acid-activated gas-generating composition and acid composition were prepared as described in EXAMPLE 1, except that sodium lauryl sulfoacetate was not present to avoid further drying of the subject's hands.
- Treatment:
- The subject's hands were treated with 10 consecutive treatment cycles, constituting a treatment session, each cycle beginning with the acid-activated gas-generating composition and ending with the acid composition to leave the skin at an acidic pH. The subject received at least three treatment sessions per week over a three month period.
- Results:
- The subject reported cessation of the steroid injections as a result of the treatment described above. Further, the subject's hands were observed to have educed flaking skin and the absence of open lesions; improved skin color, with reduced purple and grey coloration. The subject reported cessation of pain, itching, and burning as a result of the treatment sessions. The subject reported increased self-confidence and well-being due to the improvement to his hands. The subject reported a normal routine of bathing and hand washing.
- Discussion:
- Without wishing to be bound by theory, the results from the multiple treatments to the subject's hands seems to have caused both a physiological and psychological improvement to the subject. Results are physically visible. Psychological effects were also reported. The subject claims that his comfort level has never been this good since diagnosed with this affliction.
- Observed Condition Prior to Treatment:
- A 48 year old Caucasian female presented with severe dandruff. The subject had relatively thick hair at a relatively thick density. Moderate to severe dandruff was observed covering most of the scalp and even behind the ears. Dandruff was observed all over the scalp, with more pronounced symptoms towards the front hairline and the nape of the neck. The subject reported the dandruff had been a chronic condition all of her life. The subject reported that her scalp is often tight and dry feeling, and that her whole scalp was itchy.
- Compositions:
- The acid-activated gas-generating composition and acid composition were prepared as described in EXAMPLE 1.
- Treatment:
- The subject's hair and scalp was first washed with a conventional hydrating shampoo according to the manufacturer's directions. Subsequently, a treatment session including 10 treatment cycles was performed, each treatment cycle conducted by contacting the subject's hair and scalp sequentially with roughly equal volumes of the acid-activated gas-generating composition and the acid composition. Contacting the acid-activated gas-generating composition with the acid composition led to rapid gas generation and bubbling at the hair/scalp, which the subject experienced as a refreshing tingling sensation. Each treatment cycle caused the pH at the hair and scalp to cycle between alkaline and acid. After a period of several weeks, the subject returned and a second treatment session was conducted. Subsequently, further treatment sessions were conducted every five weeks for a period of several months.
- Results:
- After the first two treatment sessions, the subject's hair and scalp was examined. Compared to before the two treatment sessions, the subject's scalp was 95% free of dandruff. Very little physical appearance of dandruff was observed. The subject reported that the dryness, tight scalp and itching was ameliorated over the course of the two treatment sessions. Moreover, the subject reported that the dandruff was ameliorated after the first treatment session and was dandruff-free up to the second treatment session. The subject reported that she has never been this dandruff-free in her whole adult life, despite trying numerous shampoos and conditioners that claim to help with removing dandruff. Because the subject was in a new environment between the first and second treatment sessions, external stimuli could not be excluded as a cause of the initial dandruff amelioration after the first treatment session. However, the fact that dandruff remained ameliorated over treatment sessions subsequent to the second treatment session, when the subject had returned to her normal environment, strongly suggests that the observed dandruff amelioration was caused by the treatment sessions.
- To the extent that the term “includes” or “including” is used in the specification or the claims, it is intended to be inclusive in a manner similar to the term “comprising” as that term is interpreted when employed as a transitional word in a claim. Furthermore, to the extent that the term “or” is employed (e.g., A or B) it is intended to mean “A or B or both.” When the applicants intend to indicate “only A or B but not both” then the term “only A or B but not both” will be employed. Thus, use of the term “or” herein is the inclusive, and not the exclusive use. See Bryan A. Garner, A Dictionary of Modern Legal Usage 624 (2d. Ed. 1995). Also, to the extent that the terms “in” or “into” are used in the specification or the claims, it is intended to additionally mean “on” or “onto.” To the extent that the term “selectively” is used in the specification or the claims, it is intended to refer to a condition of a component wherein a user of the apparatus may activate or deactivate the feature or function of the component as is necessary or desired in use of the apparatus. To the extent that the terms “coupled” or “operatively connected” are used in the specification or the claims, it is intended to mean that the identified components are connected in a way to perform a designated function. To the extent that the term “substantially” is used in the specification or the claims, it is intended to mean that the identified components have the relation or qualities indicated with degree of error as would be acceptable in the subject industry.
- As used in the specification and the claims, the singular forms “a,” “an,” and “the” include the plural unless the singular is expressly specified. For example, reference to “a compound” may include a mixture of two or more compounds, as well as a single compound.
- As used herein, the term “about” in conjunction with a number is intended to include ±10% of the number. In other words, “about 10” may mean from 9 to 11.
- As used herein, the terms “optional” and “optionally” mean that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.
- In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group. As will be understood by one skilled in the art, for any and all purposes, such as in terms of providing a written description, all ranges disclosed herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, and the like. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, and the like. As will also be understood by one skilled in the art all language such as “up to,” “at least,” “greater than,” “less than,” include the number recited and refer to ranges which can be subsequently broken down into sub-ranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. For example, a group having 1-3 cells refers to groups having 1, 2, or 3 cells. Similarly, a group having 1-5 cells refers to groups having 1, 2, 3, 4, or 5 cells, and so forth. While various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art.
- As stated above, while the present application has been illustrated by the description of embodiments thereof, and while the embodiments have been described in considerable detail, it is not the intention of the applicants to restrict or in any way limit the scope of the appended claims to such detail. Additional advantages and modifications will readily appear to those skilled in the art, having the benefit of the present application. Therefore, the application, in its broader aspects, is not limited to the specific details, illustrative examples shown, or any apparatus referred to. Departures may be made from such details, examples, and apparatuses without departing from the spirit or scope of the general inventive concept.
- As used herein, “substituted” refers to an organic group as defined below (e.g., an alkyl group) in which one or more bonds to a hydrogen atom contained therein may be replaced by a bond to non-hydrogen or non-carbon atoms. Substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom may be replaced by one or more bonds, including double or triple bonds, to a heteroatom. A substituted group may be substituted with one or more substituents, unless otherwise specified. In some embodiments, a substituted group may be substituted with 1, 2, 3, 4, 5, or 6 substituents. Examples of substituent groups include: halogens (e.g., F, Cl, Br, and I); hydroxyls; alkoxy, alkenoxy, aryloxy, aralkyloxy, heterocyclyloxy, and heterocyclylalkoxy groups; carbonyls (oxo); carboxyls; esters; urethanes; oximes; hydroxylamines; alkoxyamines; aralkoxyamines; thiols; sulfides; sulfoxides; sulfones; sulfonyls; sulfonamides; amines; N-oxides; hydrazines; hydrazides; hydrazones; azides; amides; ureas; amidines; guanidines; enamines; imides; isocyanates; isothiocyanates; cyanates; thiocyanates; imines; nitro groups; or nitriles. A “per”-substituted compound or group is a compound or group having all or substantially all substitutable positions substituted with the indicated substituent. For example, 1,6-diiodo perfluoro hexane indicates a compound of formula C6F12I2, where all the substitutable hydrogens have been replaced with fluorine atoms.
- Substituted ring groups such as substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups also include rings and ring systems in which a bond to a hydrogen atom may be replaced with a bond to a carbon atom. Substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups may also be substituted with substituted or unsubstituted alkyl, alkenyl, and alkynyl groups as defined below.
- Alkyl groups include straight chain and branched chain alkyl groups having from 1 to 12 carbon atoms, and typically from 1 to 10 carbons or, in some examples, from 1 to 8, 1 to 6, or 1 to 4 carbon atoms. Examples of straight chain alkyl groups include groups such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, tert-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups. Representative substituted alkyl groups may be substituted one or more times with substituents such as those listed above and include, without limitation, haloalkyl (e.g., trifluoromethyl), hydroxyalkyl, thioalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, or carboxyalkyl.
- Cycloalkyl groups include mono-, bi- or tricyclic alkyl groups having from 3 to 12 carbon atoms in the ring(s), or, in some embodiments, 3 to 10, 3 to 8, or 3 to 4, 5, or 6 carbon atoms. Exemplary monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In some embodiments, the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments, the number of ring carbon atoms ranges from 3 to 5, 3 to 6, or 3 to 7. Bi- and tricyclic ring systems include both bridged cycloalkyl groups and fused rings, such as, but not limited to, bicyclo[2.1.1]hexane, adamantyl, or decalinyl. Substituted cycloalkyl groups may be substituted one or more times with non-hydrogen and non-carbon groups as defined above. However, substituted cycloalkyl groups also include rings that may be substituted with straight or branched chain alkyl groups as defined above. Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4-2,5- or 2,6-disubstituted cyclohexyl groups, which may be substituted with substituents such as those listed above.
- Aryl groups may be cyclic aromatic hydrocarbons that do not contain heteroatoms. Aryl groups herein include monocyclic, bicyclic and tricyclic ring systems. Aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, fluorenyl, phenanthrenyl, anthracenyl, indenyl, indanyl, pentalenyl, and naphthyl groups. In some embodiments, aryl groups contain 6-14 carbons, and in others from 6 to 12 or even 6-10 carbon atoms in the ring portions of the groups. In some embodiments, the aryl groups may be phenyl or naphthyl. Although the phrase “aryl groups” may include groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl or tetrahydronaphthyl), “aryl groups” does not include aryl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members. Rather, groups such as tolyl may be referred to as substituted aryl groups. Representative substituted aryl groups may be mono-substituted or substituted more than once. For example, monosubstituted aryl groups include, but are not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl, which may be substituted with substituents such as those above.
- Aralkyl groups may be alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group may be replaced with a bond to an aryl group as defined above. In some embodiments, aralkyl groups contain 7 to 16 carbon atoms, 7 to 14 carbon atoms, or 7 to 10 carbon atoms. Substituted aralkyl groups may be substituted at the alkyl, the aryl or both the alkyl and aryl portions of the group. Representative aralkyl groups include but are not limited to benzyl and phenethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-indanylethyl. Substituted aralkyls may be substituted one or more times with substituents as listed above.
- Groups described herein having two or more points of attachment (e.g., divalent, trivalent, or polyvalent) within the compound of the technology may be designated by use of the suffix, “ene.” For example, divalent alkyl groups may be alkylene groups, divalent aryl groups may be arylene groups, divalent heteroaryl groups may be heteroarylene groups, and so forth. In particular, certain polymers may be described by use of the suffix “ene” in conjunction with a term describing the polymer repeat unit.
- Alkoxy groups may be hydroxyl groups (—OH) in which the bond to the hydrogen atom may be replaced by a bond to a carbon atom of a substituted or unsubstituted alkyl group as defined above. Examples of linear alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy. Examples of branched alkoxy groups include, but are not limited to, isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, or isohexoxy. Examples of cycloalkoxy groups include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, or cyclohexyloxy. Representative substituted alkoxy groups may be substituted one or more times with substituents such as those listed above.
- The term “amine” (or “amino”), as used herein, refers to NR5R6 groups, wherein R5 and R6 may be independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein. In some embodiments, the amine may be alkylamino, dialkylamino, arylamino, or alkylarylamino. In other embodiments, the amine may be NH2, methylamino, dimethylamino, ethylamino, diethylamino, propylamino, isopropylamino, phenylamino, or benzylamino. The term “alkylamino” may be defined as NR7R8, wherein at least one of R7 and R8 may be alkyl and the other may be alkyl or hydrogen. The term “arylamino” may be defined as NR9R10, wherein at least one of R9 and R10 may be aryl and the other may be aryl or hydrogen.
- The term “halogen” or “halo,” as used herein, refers to bromine, chlorine, fluorine, or iodine. In some embodiments, the halogen may be fluorine. In other embodiments, the halogen may be chlorine or bromine.
- The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the following claims.
Claims (36)
1. A method for treating a keratinized tissue condition in a subject in need thereof, comprising:
conducting one or more treatment cycles on the keratinized tissue, each treatment cycle comprising:
contacting the keratinized tissue with an acid-activated gas-generating composition;
contacting the keratinized tissue with an acid composition; and
allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue.
2. The method of claim 1 , the keratinized tissue condition being at least partly ameliorated.
3. The method of claim 1 , the keratinized tissue condition comprising one or more of: acneiform eruptions, autoinflammatory syndromes, chronic blistering, conditions of the skin appendages, dermatitis, drug or agent eruptions, infection-related, papulosquamous hyperkeratosis, palmoplantar keratodermas, pruritis, psoriasis, conditions resulting from physical factors, or ionizing radiation-induced conditions.
4. The method of claim 1 , at least one treatment cycle comprising contacting the keratinized tissue with the acid-activated gas-generating composition before contacting the keratinized tissue with the acid composition.
5. The method of claim 4 , at least one treatment cycle comprising contacting the keratinized tissue with the acid composition before contacting the keratinized tissue with the acid-activated gas-generating composition.
6. The method of claim 1 , further comprising conducting two or more of the treatment cycles in succession on the keratinized tissue.
7. The method of claim 1 , at least one treatment cycle comprising rinsing the keratinized tissue after allowing the acid composition and the acid-activated gas-generating composition to react effective to generate the gas at the keratinized tissue.
8. The method of claim 1 , at least one treatment cycle comprising contacting the keratinized tissue with the acid composition after conducting the one or more treatment cycles on the keratinized tissue.
9. The method of claim 1 , further comprising adjusting the keratinized tissue to between a pH of about 4.5 and a pH of about 6.5 after conducting the one or more treatment cycles on the keratinized tissue.
10. The method of claim 1 , the acid-activated gas-generating composition comprising one or more gas generating agents comprising one or more of: an alkali metal carbonate, alkali earth metal carbonate, an alkali metal bicarbonate, an alkali earth metal bicarbonate, or carbonic acid.
11. The method of claim 1 , the acid composition comprising an acid comprising one or more of: lactic acid, acetic acid, formic acid, citric acid, oxalic acid, phosphoric acid, succinic acid, uric acid, or an acidic ammonium salt.
12. The method of claim 1 , the acid-activated gas-generating composition and the acid composition each independently comprising one or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, a sugar, or sea trace elements
13. The method of claim 1 , the acid activated gas generating composition comprising: sodium hydrogen carbonate, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt; and a sugar.
14. The method of claim 1 , the acid composition comprising citric acid, sodium chloride, magnesium chloride, dextrose, and sea trace elements.
15. The method of claim 1 , at least one of the one or more treatment cycles causing the keratinized tissue to vary in pH between an alkaline state and an acidic state.
16. The method of claim 1 , the keratinized tissue comprising a plurality of cuticles, at least one of the one or more treatment cycles varying a pH value at the keratinized tissue effective to cause at least a portion of the plurality of cuticles to switch between an open state and a closed state.
17. The method of claim 1 , the keratinized tissue comprising a plurality of keratinized epidermal skin cells, at least one of the one or more treatment cycles causing a pH at the keratinized tissue to vary effective to cause at least a portion of the plurality of keratinized epidermal skin cells to be shed from the keratinized tissue.
18. The method of claim 1 , further comprising: preparing the acid-activated gas-generating composition by contacting a precursor of the acid-activated gas-generating composition with one or more of: water or a slip composition, the slip composition comprising one or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, or sea trace elements.
19. The method of claim 1 , further comprising: preparing the acid composition by contacting a precursor of the acid composition with one or more of: water or a slip composition, the slip composition comprising one or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, or sea trace elements.
20. A kit configured for treating a keratinized tissue condition in a subject in need thereof, comprising:
an acid-activated gas-generating composition or a precursor thereof comprised by a first reservoir;
an acid composition or a precursor thereof comprised by a second reservoir separated from the first reservoir;
instructions, the instructions comprising directions to conduct one or more treatment cycles on the keratinized tissue, each treatment cycle comprising:
contacting the keratinized tissue with the acid-activated gas-generating composition;
contacting the keratinized tissue with the acid composition; and
allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue.
21. The kit of claim 23 , the first reservoir comprising the precursor of the acid-activated gas-generating composition, the kit further comprising:
a slip composition comprised by a third reservoir, the slip composition comprising one or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, or sea trace elements; and
instructions to combine the slip composition with the precursor of the acid-activated gas-generating composition in the first reservoir to form the acid-activated gas-generating composition.
22. The kit of claim 23 , the first reservoir comprising the precursor of the acid-activated gas-generating composition, the kit further comprising instructions to contact water to the precursor of the acid-activated gas-generating composition in the first reservoir.
23. The kit of claim 23 , the second reservoir comprising the precursor of the acid composition, the kit further comprising:
a slip composition comprised by a third reservoir, the slip composition comprising one or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, or sea trace elements; and
instructions to combine the slip composition with the precursor of the acid composition in the second reservoir to form the acid composition.
24. The kit of claim 23 , the second reservoir comprising the precursor of the acid composition, the kit further comprising instructions to contact water to the precursor of the acid composition in the second reservoir.
25. The kit of claim 23 , the instructions comprising conducting one or more treatment sessions over a period of time until the keratinized tissue condition is at least partly ameliorated, each of the one or more treatment sessions comprising conducting the one or more treatment cycles on the keratinized tissue.
26. The kit of claim 23 , the instructions comprising conducting the one or more treatment cycles to treat a keratinized tissue condition of the keratinized tissue, the keratinized tissue condition comprising one or more of: acneiform eruptions, autoinflammatory syndromes, chronic blistering, conditions of the skin appendages, dermatitis, drug or agent eruptions, infection-related, papulosquamous hyperkeratosis, palmoplantar keratodermas, pruritis, psoriasis, conditions resulting from physical factors, or ionizing radiation-induced conditions.
27. The kit of claim 23 , the instructions further comprising conducting one or more of:
at least one treatment cycle comprising contacting the keratinized tissue with the acid-activated gas-generating composition before contacting the keratinized tissue with the acid composition;
at least one treatment cycle comprising contacting the keratinized tissue with the acid composition before contacting the keratinized tissue with the acid-activated gas-generating composition;
at least one treatment cycle comprising rinsing the keratinized tissue after allowing the acid composition and the acid-activated gas-generating composition to react effective to generate the gas at the keratinized tissue;
at least one treatment cycle comprising contacting the keratinized tissue with the acid composition after conducting the one or more treatment cycles on the keratinized tissue; or
two or more of the treatment cycles in succession on the keratinized tissue.
28. The kit of claim 23 , the instructions further comprising adjusting the keratinized tissue to between a pH of about 4.5 and a pH of about 6.5 after conducting the one or more treatment cycles on the keratinized tissue.
29. The kit of claim 23 , the instructions further comprising conducting at least one of the one or more treatment cycles effective to cause the keratinized tissue to vary in pH between an alkaline state and an acidic state.
30. The kit of claim 23 , the instructions further comprising conducting, on the keratinized tissue, the keratinized tissue comprising a plurality of cuticles, at least one of the one or more treatment cycles to vary a pH value at the keratinized tissue effective to cause at least a portion of the plurality of cuticles to switch between an open state and a closed state.
31. The kit of claim 23 , the instructions further comprising conducting, on the keratinized tissue, the keratinized tissue comprising a plurality of keratinized epidermal skin cells, at least one of the one or more treatment cycles to cause a pH at the keratinized tissue to vary effective to cause at least a portion of the plurality of keratinized epidermal skin cells to be shed from the keratinized tissue.
32. The kit of claim 23 , the acid-activated gas-generating composition or the precursor thereof comprising one or more gas generating agents comprising one or more of: an alkali metal carbonate, alkali earth metal carbonate, an alkali metal bicarbonate, an alkali earth metal bicarbonate, or carbonic acid.
33. The kit of claim 23 , the acid composition or the precursor thereof comprising an acid comprising one or more of: lactic acid, acetic acid, formic acid, citric acid, oxalic acid, phosphoric acid, succinic acid, uric acid, or an acidic ammonium salt.
34. The kit of claim 23 , the acid-activated gas-generating composition and the acid composition each independently comprising one or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, a sugar, or sea trace elements
35. The kit of claim 23 , the acid activated gas generating composition comprising sodium hydrogen carbonate, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt; and a sugar.
36. The kit of claim 23 , the acid composition comprising citric acid, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt; and a sugar.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/214,930 US20150258011A1 (en) | 2014-03-15 | 2014-03-15 | Treatment of keratinized tissues |
| CA2850650A CA2850650A1 (en) | 2014-03-15 | 2014-04-30 | Treatment of keratinized tissues |
| US15/439,636 US10166180B2 (en) | 2014-03-15 | 2017-02-22 | Treatment of keratinized tissues |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/214,930 US20150258011A1 (en) | 2014-03-15 | 2014-03-15 | Treatment of keratinized tissues |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/439,636 Division US10166180B2 (en) | 2014-03-15 | 2017-02-22 | Treatment of keratinized tissues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20150258011A1 true US20150258011A1 (en) | 2015-09-17 |
Family
ID=54067747
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/214,930 Abandoned US20150258011A1 (en) | 2014-03-15 | 2014-03-15 | Treatment of keratinized tissues |
| US15/439,636 Active US10166180B2 (en) | 2014-03-15 | 2017-02-22 | Treatment of keratinized tissues |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/439,636 Active US10166180B2 (en) | 2014-03-15 | 2017-02-22 | Treatment of keratinized tissues |
Country Status (2)
| Country | Link |
|---|---|
| US (2) | US20150258011A1 (en) |
| CA (1) | CA2850650A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46164E1 (en) | 2010-07-14 | 2016-09-27 | Rcm Enterprise Llc | Mechanical prosthetic finger device |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000027356A1 (en) * | 1998-11-10 | 2000-05-18 | Color Access, Inc. | Self-foaming cleansing systems |
| US20090214628A1 (en) * | 2004-09-27 | 2009-08-27 | De Rijk Jan | Methods and compositions for treatment of skin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120076738A1 (en) * | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
-
2014
- 2014-03-15 US US14/214,930 patent/US20150258011A1/en not_active Abandoned
- 2014-04-30 CA CA2850650A patent/CA2850650A1/en not_active Abandoned
-
2017
- 2017-02-22 US US15/439,636 patent/US10166180B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000027356A1 (en) * | 1998-11-10 | 2000-05-18 | Color Access, Inc. | Self-foaming cleansing systems |
| US20090214628A1 (en) * | 2004-09-27 | 2009-08-27 | De Rijk Jan | Methods and compositions for treatment of skin |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46164E1 (en) | 2010-07-14 | 2016-09-27 | Rcm Enterprise Llc | Mechanical prosthetic finger device |
Also Published As
| Publication number | Publication date |
|---|---|
| US10166180B2 (en) | 2019-01-01 |
| CA2850650A1 (en) | 2015-09-15 |
| US20170157033A1 (en) | 2017-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104983607B (en) | One kind massage essential oil and preparation method and application | |
| CN107157804B (en) | A kind of nutrition scalp hair follicles hair tonic elite and preparation method thereof | |
| EP4132459A1 (en) | Composition for the making of an emulsifiable triphasic formulation, and kit for the use of such composition | |
| EA202092820A1 (en) | MUSCLE RELAXATION COMPOSITION | |
| US10166180B2 (en) | Treatment of keratinized tissues | |
| CN111803397B (en) | Scalp care product and preparation method thereof | |
| US20190142732A1 (en) | Human body cleaner and manufacturing method thereof | |
| CN104287982B (en) | Dandruff removal composition for adjusting oil balance of scalp | |
| WO2008050157A2 (en) | Ozonated oil formulations | |
| US20060269615A1 (en) | Topical treatment for skin irritation | |
| RU2489139C2 (en) | Local composition for immediate and intense lifting effect | |
| HUP0401422A2 (en) | Use of l-arginine as vasoaktive ingredient absorbing through skin for external application | |
| KR100795993B1 (en) | Cosmetic composition for atopic skin | |
| JP5824704B1 (en) | Powder-like stagnation agent | |
| CN114948830A (en) | Functional medical cleaning wet tissue liquid for human body | |
| US9757326B2 (en) | Hair rejuvenating lotion | |
| CN119745747B (en) | Composition for relieving sensitive skin itch and improving barrier and application thereof | |
| RU2732295C1 (en) | Preparation for strengthening and stimulating hair growth and method of using it | |
| CN111728903B (en) | Injection and cosmetic composition containing lemon balm extract as active ingredient | |
| US20080026074A1 (en) | Method of short term skin wrinkles correction using strontium divalent ion | |
| Setiawan | The Effectiveness of Aloe Vera in Multiple Moist Spray Products as a Hair Tonic to Reduce Students Scalp Irritation | |
| CN110812288A (en) | Soothing and moisturizing cosmetic composition and amino acid facial cleanser | |
| KR101851559B1 (en) | Compositions for activating NGF and anti-aging cosmetic composition containing the same | |
| Karimova | EVALUATION OF THE EFFICACY OF AN OINTMENT CONTAINING GOOSE FAT, EXTRACT ALOE, AND BETAMETHASONE IN PRECLINICAL STUDIES FOR THE TREATMENT OF ALLERGIC DERMATITIS | |
| CN117503651A (en) | A nutritional composition for improving rough skin by ultrasonic or radio frequency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |